Cargando…
Feasibility of classical secondary hormonal therapies prior to docetaxel therapy in Japanese patients with castration-resistant prostate cancer: Multicenter retrospective study
BACKGROUND: We retrospectively analyzed castration-resistant prostate cancer (CRPC) patients treated with secondary hormonal therapies (SHTs) prior to docetaxel therapy. METHODS: The cases of 73 CRPC patients who underwent docetaxel therapy in 2005–2011 at four hospitals in Ibaraki, Japan were analy...
Autores principales: | Kandori, Shuya, Yoshino, Takayuki, Tsutsumi, Masakazu, Yamauchi, Atsushi, Ohtani, Mikinobu, Fukuhara, Yoshiharu, Miyanaga, Naoto, Miyazaki, Jun, Nishiyama, Hiroyuki, Shimazui, Toru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153431/ https://www.ncbi.nlm.nih.gov/pubmed/27995113 http://dx.doi.org/10.1016/j.prnil.2016.09.001 |
Ejemplares similares
-
Phospholipase D2 promotes disease progression of renal cell carcinoma through the induction of angiogenin
por: Kandori, Shuya, et al.
Publicado: (2018) -
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014) -
Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
por: Scagliotti, G V, et al.
Publicado: (2006) -
Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015) -
Granulocyte colony‐stimulating factor associated arteritis in a patient with castration‐resistant prostate cancer
por: Nitta, Satoshi, et al.
Publicado: (2021)